Cancer stem cells (CSCs) are a challenge in cancer treatment due to their therapy resistance. We demonstrated that enhanced Notch signaling in breast cancer promotes self-renewal of CSCs that display high glycolytic activity and aggressive hormone-independent tumor growth in vivo. We took advantage of the glycolytic phenotype and the dependence on Notch activity of the CSCs and designed nanoparticles to target the CSCs. Mesoporous silica nanoparticles were functionalized with glucose moieties and loaded with a gamma-secretase inhibitor, a potent interceptor of Notch signaling. Cancer cells and CSCs in vitro and in vivo efficiently internalized these particles, and particle uptake correlated with the glycolytic profile of the cells. Nanopart...
Notch signaling, a key regulator of stem cells, is frequently overactivated in cancer. It is often l...
Notch signaling, a key regulator of stem cells, is frequently overactivated in cancer. It is often l...
Notch signaling, a key regulator of stem cells, is frequently overactivated in cancer. It is often l...
Cancer stem cells (CSCs) are a challenge in cancer treatment due to their therapy resistance. We dem...
Cancer stem cells (CSCs) are a challenge in cancer treatment due to their therapy resistance. We dem...
Cancer stem cells (CSCs) are a challenge in cancer treatment due to their therapy resistance. We dem...
Cancer stem cells (CSCs) are a challenge in cancer treatment due to their therapy resistance. We dem...
Cancer stem cells (CSCs) are a challenge in cancer treatment due to their therapy resistance. We dem...
\u3cp\u3eCancer stem cells (CSCs) are a challenge in cancer treatment due to their therapy resistanc...
Cancer stem cells (CSCs) are a challenge in cancer treatment due to their therapy resistance. We dem...
Cancer stem cells (CSCs) are a challenge in cancer treatment due to their therapy resistance. We dem...
Cancer stem cells (CSCs) are a challenge in cancer treatment due to their therapy resistance. We dem...
Notch signaling, a key regulator of stem cells, is frequently overactivated in cancer. It is often l...
Notch signaling, a key regulator of stem cells, is frequently overactivated in cancer. It is often l...
Notch signaling, a key regulator of stem cells, is frequently overactivated in cancer. It is often l...
Notch signaling, a key regulator of stem cells, is frequently overactivated in cancer. It is often l...
Notch signaling, a key regulator of stem cells, is frequently overactivated in cancer. It is often l...
Notch signaling, a key regulator of stem cells, is frequently overactivated in cancer. It is often l...
Cancer stem cells (CSCs) are a challenge in cancer treatment due to their therapy resistance. We dem...
Cancer stem cells (CSCs) are a challenge in cancer treatment due to their therapy resistance. We dem...
Cancer stem cells (CSCs) are a challenge in cancer treatment due to their therapy resistance. We dem...
Cancer stem cells (CSCs) are a challenge in cancer treatment due to their therapy resistance. We dem...
Cancer stem cells (CSCs) are a challenge in cancer treatment due to their therapy resistance. We dem...
\u3cp\u3eCancer stem cells (CSCs) are a challenge in cancer treatment due to their therapy resistanc...
Cancer stem cells (CSCs) are a challenge in cancer treatment due to their therapy resistance. We dem...
Cancer stem cells (CSCs) are a challenge in cancer treatment due to their therapy resistance. We dem...
Cancer stem cells (CSCs) are a challenge in cancer treatment due to their therapy resistance. We dem...
Notch signaling, a key regulator of stem cells, is frequently overactivated in cancer. It is often l...
Notch signaling, a key regulator of stem cells, is frequently overactivated in cancer. It is often l...
Notch signaling, a key regulator of stem cells, is frequently overactivated in cancer. It is often l...
Notch signaling, a key regulator of stem cells, is frequently overactivated in cancer. It is often l...
Notch signaling, a key regulator of stem cells, is frequently overactivated in cancer. It is often l...
Notch signaling, a key regulator of stem cells, is frequently overactivated in cancer. It is often l...